BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines.
What BALAXI files
- Others58
- Important17
- Board Meeting12
- PPTs8
- Credit Ratings3
- Insider Trade3
Balaxi Pharmaceuticals reported zero activity regarding physical share transfer re-lodgements for the period. Zero requests were received, processed, approved, or rejected, indicating a settled holding structure with no operational impact on equity or liquidity for retail investors.
Balaxi Pharma's RTA reports no requests were received or processed for physical share re-lodgements. This indicates a quiet period with no activity in physical transfer requests.
Balaxi Pharmaceuticals commenced commercial production at its new pharma plant, launching 2 products. The company secured approvals for 29 additional products, expanding its portfolio to 31, and is progressing towards WHO-GMP certification. Consolidated Q1 revenue was 80.68 Cr, with a net profit of 1.30 Cr.
Balaxi Pharma established a manufacturing facility, with operations expected to commence in H1 FY27. The company acquired Balaxi Healthcare Nicaragua as a wholly owned subsidiary and struck off its Centrafrique unit. It maintains its focus on 100% international wholesale pharmaceutical trading.
Balaxi Pharma's Registrar & Share Transfer Agent confirmed no re-lodgement requests for physical shares were received or processed for June 2026, indicating no investor activity in this transfer window.